• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Biotech firm plans stock sale

Article

Cytogen plans to sell 2.57 million shares of its common stock at $10.10 per share through a registered direct offering. The transaction is expected to net the company $24 million. Founded in 1980, Princeton, NJ-based Cytogen develops and commercializes

Cytogen plans to sell 2.57 million shares of its common stock at $10.10 per share through a registered direct offering. The transaction is expected to net the company $24 million. Founded in 1980, Princeton, NJ-based Cytogen develops and commercializes oncology products, including the pain management product Quadramet and diagnostic radiopharmaceutical Prostascint. The company has exclusive U.S. marketing rights to Combidex, an investigational MR agent designed to aid in the diagnosis of metastatic lymph nodes.

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.